TuHURA BIOSCIENCES, INC./NV Fair Value, Concentration of Risk, Derivative Instruments, Liabilities
TuHURA BIOSCIENCES, INC./NV (HURA) had Fair Value, Concentration of Risk, Derivative Instruments, Liabilities of $3.39 thousand as of 2018-03-31, per its 10-Q filed 2018-05-15.
Discontinued › Notes › Fair Value Disclosures
us-gaap:FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities · last filed 2018-05-15
- 2018-03-31: Fair Value, Concentration of Risk, Derivative Instruments, Liabilities $3.39K.
- 2017-12-31: Fair Value, Concentration of Risk, Derivative Instruments, Liabilities $5.55K.
- 2017-06-30: Fair Value, Concentration of Risk, Derivative Instruments, Liabilities $61.23K.
- 2017-03-31: Fair Value, Concentration of Risk, Derivative Instruments, Liabilities $248.69K.
| Period end | Fair Value, Concentration of Risk, Derivative Instruments, Liabilities |
|---|---|
| 2018-03-31 | $3.39K 10-Q · filed 2018-05-15 |
| 2017-12-31 | $5.55K 10-Q · filed 2018-05-15 |
| 2017-06-30 | $61.23K 10-Q · filed 2018-05-15 |
| 2017-03-31 | $248.69K 10-Q · filed 2018-05-15 |
| 2016-12-31 | $171.21K 10-Q · filed 2018-05-15 |
| 2016-06-30 | $693.70K 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |